Your browser doesn't support javascript.
loading
Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
Hlady, Ryan A; Zhao, Xia; El Khoury, Louis Y; Luna, Aesis; Pham, Kien; Wu, Qunfeng; Lee, Jeong-Heon; Pyrsopoulos, Nikolaos T; Liu, Chen; Robertson, Keith D.
Afiliação
  • Hlady RA; Department of Molecular Pharmacology and Experimental TherapeuticsMayo ClinicRochesterMinnesotaUSA.
  • Zhao X; Department of Molecular Pharmacology and Experimental TherapeuticsMayo ClinicRochesterMinnesotaUSA.
  • El Khoury LY; Department of Molecular Pharmacology and Experimental TherapeuticsMayo ClinicRochesterMinnesotaUSA.
  • Luna A; Department of PathologyYale School of MedicineNew HavenConnecticutUSA.
  • Pham K; Department of PathologyYale School of MedicineNew HavenConnecticutUSA.
  • Wu Q; Department of Pathology and Laboratory MedicineNew Jersey Medical SchoolRutgersThe State University of New JerseyNewarkNew JerseyUSA.
  • Lee JH; Department of Biochemistry and Molecular BiologyMayo ClinicRochesterMinnesotaUSA.
  • Pyrsopoulos NT; Department of MedicineRutgers New Jersey Medical SchoolNewarkNew JerseyUSA.
  • Liu C; Department of PathologyYale School of MedicineNew HavenConnecticutUSA.
  • Robertson KD; Department of Molecular Pharmacology and Experimental TherapeuticsMayo ClinicRochesterMinnesotaUSA.
Hepatology ; 75(4): 983-996, 2022 04.
Article em En | MEDLINE | ID: mdl-34387871

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Carcinoma Hepatocelular / Hepatite C Crônica / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Carcinoma Hepatocelular / Hepatite C Crônica / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article